SEC Tracker
Get the app
RPRX · XBRL financial data

Royalty Pharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (RPRX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Revenue596*568537565594*568579609622*631674690
Research and development1*1111*513015151*409863
General and administrative59*58555768*111180119164*159162150
Operating income (loss)613*(74)270735362*534210427388*563133411
Interest expense47*44496766*65698094*949490
Other income (expense)(18)*(4)6(2)(2)*(3)(2)(2)(8)*(2)(1)(2)
Income tax expense (benefit)0*0000*0000*000
Net income (loss)494*5102544208*23830288214*29518145
Earnings per share, basic USD per share1.11*0.010.231.220.47*0.550.070.670.50*0.670.040.32
Earnings per share, diluted USD per share—0.010.231.21—0.550.070.67—0.670.040.32
Weighted average shares, basic millions of shares446*449451448446*435424432428*437445446
Weighted average shares, diluted millions of shares597*597597593589*578562560558*557557557

Balance sheet

CSV

Fiscal quarters (RPRX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents4778431,7659509291,088632939619586812514
Marketable securities182939495812131619222531
Marketable securities, non-current437474630657694219272303419407372350
Total current assets1,2741,5602,5791,7941,8021,8431,5201,8501,5281,4261,7651,526
Goodwill————0—925925925925924924
Total assets16,38216,13117,65718,04218,22317,60818,32319,34719,62119,81519,82019,461
Current portion of long-term debt000997998999999380380380380997
Total current liabilities1611252761,1681,2541,1831,2075316365366311,179
Long-term debt6,1356,1397,6026,6106,6156,6197,0038,5668,5718,5768,5827,591
Total liabilities6,2986,2677,9057,7847,8807,8208,8209,7269,9069,87910,0349,666
Retained earnings2,5182,4272,3782,7652,8462,4812,2232,3042,3562,5072,4592,499
Total liabilities and equity16,38216,13117,65718,04218,22317,60818,32319,34719,62119,81519,82019,461

Cash flows

CSV

Fiscal quarters (RPRX's year ends in late December)

In millions of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)494*5102544208*23830288214*29518145
Stock-based compensation1*11*1*1*191*73*126*122107*105*
Net cash from operating activities773*665658*704*743*596364*703*827*718728*686*
Net cash from investing activities(1,000)*(87)(893)*(1,193)*(506)*504(312)*(958)*(848)*(478)(230)*(286)*
Share repurchases30*080*97*53*709292*146*81*5045*86*
Net cash from financing activities(232)*(212)1,157*(326)*(258)*(941)(508)*563*(300)*(273)(273)*(699)*
Net change in cash(459)*366922*(815)*(21)*159(456)*307*(320)*(32)226*(298)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Royalty Pharma514690686*not reported— 10-QSep 30, 2026
Teva Pharmaceutical Industries4,0854,3952411.2B— 10-QSep 30, 2026
Biogen1,3042,804641*147.8M— 10-QSep 30, 2026
BeOne Medicines5,7811,890509*1.5B— 10-QSep 30, 2026
INSMED397524(36)*219.4M— 10-QSep 30, 2026
United Therapeutics1,189833307*42.6M— 10-QSep 30, 2026
Roivant Sciences1,2481.4(271)722.3M14.2 quarters 10-QJun 30, 2026
Neurocrine Biosciences6421,123395*101.2M— 10-QSep 30, 2026
Exelixis305659280*244.0M— 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.